Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.46 |
| ▸ | WEE1 | P30291 | 2/20 | 0.43 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.43 |
| ▸ | GRK2 | P25098 | 1/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | BTK | Q06187 | 4/20 | 0.33 |
| ▸ | TEC | P42680 | 2/20 | 0.33 |
| ▸ | BMX | P51813 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | LYN | P07948 | 2/20 | 0.33 |
| ▸ | TXK | P42681 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | HCK | P08631 | 1/20 | 0.33 |
| ▸ | FGR | P09769 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15005586 | 0.81 | CDK2 (0.40) | CCNA2CDK2CCNA1WEE1PKMYT1 | |
| SCHEMBL24112905 | 0.74 | WEE1 (0.52) | CCNA2CDK2CCNA1WEE1PKMYT1 | |
| SCHEMBL5224979 | 0.73 | CCNA2 (0.48) | CCNA2CDK2CCNA1WEE1PKMYT1 | |
| SCHEMBL3598556 | 0.72 | CDK2 (0.44) | CCNA2CDK2CCNA1WEE1PKMYT1 | |
| SCHEMBL3592925 | 0.71 | KDM4E (0.43) | CCNA2CDK2CCNA1 | |
| SCHEMBL3599692 | 0.70 | PKM (0.43) | EGFR | |
| SCHEMBL5205571 | 0.69 | CCNA2 (0.53) | CCNA2CDK2CCNA1WEE1PKMYT1 | |
| SCHEMBL5225569 | 0.68 | CCNA2 (0.52) | CCNA2CDK2CCNA1RIPK2 | |
| SCHEMBL5230469 | 0.68 | CDK2 (0.52) | CCNA2CDK2CCNA1ROCK2CYP3A4 | |
| SCHEMBL3601342 | 0.68 | KDM4E (0.40) | CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118102-B1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-06-12 | — | — | EP | claimed |
| US-8207180-B2 | Tricyclic indoles and (4,5-dihydro) indoles | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-26 | — | — | US | claimed |
| US-20100075998-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-03-25 | — | — | US | claimed |
| EP-2118102-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | Nerviano Medical Sciences S.r.l. (IT) | 2009-11-18 | — | — | EP | claimed |
| WO-2008065054-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-05 | — | — | WO | claimed |
| EP-2118102-B1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-06-12 | — | — | EP | disclosed |
| US-8207180-B2 | Tricyclic indoles and (4,5-dihydro) indoles | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-26 | — | — | US | disclosed |
| US-20100075998-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-03-25 | — | — | US | disclosed |
| EP-2118102-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | Nerviano Medical Sciences S.r.l. (IT) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008065054-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075998-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | CDC7, CDK7, CDK17 | CCNA2 75/4885CDK2 9/4885CCNA1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.